{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T20:59:44Z","timestamp":1773694784895,"version":"3.50.1"},"reference-count":46,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1016\/j.bulcan.2017.11.007","type":"journal-article","created":{"date-parts":[[2017,12,23]],"date-time":"2017-12-23T20:04:10Z","timestamp":1514059450000},"page":"35-45","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["H\u00e9t\u00e9rog\u00e9n\u00e9it\u00e9 mol\u00e9culaire des m\u00e9soth\u00e9liomes pleuraux malins"],"prefix":"10.1016","volume":"105","author":[{"given":"Robin","family":"Tranchant","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7ois","family":"Montagne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-Claude","family":"Jaurand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Didier","family":"Jean","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bulcan.2017.11.007_bib0235","series-title":"Amiante et m\u00e9soth\u00e9liome pleural malin","author":"INCa","year":"2011"},{"key":"10.1016\/j.bulcan.2017.11.007_bib0240","first-page":"26","article-title":"Amiante et effets sur la sant\u00e9\u00a0: une th\u00e9matique toujours d\u2019actualit\u00e9","volume":"3\u20134","author":"Pairon","year":"2015","journal-title":"Bull Epidemiol Hebd"},{"key":"10.1016\/j.bulcan.2017.11.007_bib0245","series-title":"Pathobiology of human disease: a dynamic encyclopedia of disease mechanisms","first-page":"2690","article-title":"Thoracic Neoplasia-Mesothelioma","author":"Jean","year":"2014"},{"key":"10.1016\/j.bulcan.2017.11.007_bib0250","doi-asserted-by":"crossref","first-page":"219","DOI":"10.2217\/lmt.15.21","article-title":"Causes and pathophysiology of malignant pleural mesothelioma","volume":"4","author":"Jean","year":"2015","journal-title":"Lung Cancer Management"},{"key":"10.1016\/j.bulcan.2017.11.007_bib0255","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1080\/10937404.2016.1193361","article-title":"Five years update on relationships between malignant pleural mesothelioma and exposure to asbestos and other elongated mineral particles","volume":"19","author":"Andujar","year":"2016","journal-title":"J Toxicol Environ Health B Crit Rev"},{"key":"10.1016\/j.bulcan.2017.11.007_bib0260","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1164\/rccm.201210-1911OC","article-title":"Pleural mesothelioma and occupational coexposure to asbestos, mineral wool, and silica","volume":"187","author":"Lacourt","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.bulcan.2017.11.007_bib0265","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/978-3-642-10862-4_8","article-title":"Chemotherapy and radiotherapy for mesothelioma","volume":"189","author":"Dhalluin","year":"2011","journal-title":"Recent Results Cancer Res"},{"key":"10.1016\/j.bulcan.2017.11.007_bib0270","first-page":"S238","article-title":"Management of malignant pleural mesothelioma \u2013 The European experience","volume":"6","author":"Opitz","year":"2014","journal-title":"J Thorac Dis"},{"key":"10.1016\/j.bulcan.2017.11.007_bib0275","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1159\/000339259","article-title":"Malignant pleural mesothelioma: from the bench to the bedside","volume":"83","author":"Astoul","year":"2012","journal-title":"Respiration"},{"key":"10.1016\/j.bulcan.2017.11.007_bib0280","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1093\/annonc\/mdv101","article-title":"Searching for targets for the systemic therapy of mesothelioma","volume":"26","author":"Stahel","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bulcan.2017.11.007_bib0285","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/S0140-6736(15)01238-6","article-title":"Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3\u00a0trial","volume":"387","author":"Zalcman","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.bulcan.2017.11.007_bib0290","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.18_suppl.LBA8507","article-title":"Second- or third-line nivolumab (Nivo) versus nivo plus ipilimumab (Ipi) in malignant pleural mesothelioma (MPM) patients: results of the IFCT-1501\u00a0MAPS2\u00a0randomized phase II trial","volume":"35","author":"Scherpereel","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2017.11.007_bib0295","doi-asserted-by":"crossref","first-page":"647","DOI":"10.5858\/arpa.2012-0214-OA","article-title":"Guidelines for pathologic diagnosis of malignant mesothelioma: 2012\u00a0update of the consensus statement from the International Mesothelioma Interest Group","volume":"137","author":"Husain","year":"2013","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.bulcan.2017.11.007_bib0300","doi-asserted-by":"crossref","first-page":"277","DOI":"10.5858\/arpa.2011-0215-RA","article-title":"Molecular changes in mesothelioma with an impact on prognosis and treatment","volume":"136","author":"Jean","year":"2012","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.bulcan.2017.11.007_bib0305","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1517\/14656560802631285","article-title":"Chemotherapy of malignant pleural mesothelioma","volume":"10","author":"Bertino","year":"2009","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.bulcan.2017.11.007_bib0310","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1200\/JCO.2011.41.5869","article-title":"Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine\/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma","volume":"30","author":"Kindler","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2017.11.007_bib0315","doi-asserted-by":"crossref","first-page":"253","DOI":"10.5858\/arpa.2010-0604-RA","article-title":"Immunohistochemistry and molecular diagnostics of pleural malignant mesothelioma","volume":"136","author":"Betta","year":"2012","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.bulcan.2017.11.007_bib0320","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1080\/10937404.2011.556051","article-title":"Role of mutagenicity in asbestos fiber-induced carcinogenicity and other diseases","volume":"14","author":"Huang","year":"2011","journal-title":"J Toxicol Environ Health B Crit Rev"},{"key":"10.1016\/j.bulcan.2017.11.007_bib0325","doi-asserted-by":"crossref","first-page":"13432","DOI":"10.1073\/pnas.1612074113","article-title":"High-density array-CGH with targeted NGS unmask multiple noncontiguous minute deletions on chromosome 3p21\u00a0in mesothelioma","volume":"113","author":"Yoshikawa","year":"2016","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.bulcan.2017.11.007_bib0330","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.ajpath.2010.10.039","article-title":"Syntenic Relationships between genomic profiles of fiber-induced murine and human malignant mesothelioma","volume":"178","author":"Jean","year":"2011","journal-title":"Am J Pathol"},{"key":"10.1016\/j.bulcan.2017.11.007_bib0335","first-page":"1","article-title":"Genome-wide analysis of abdominal and pleural malignant mesothelioma with DNA arrays reveals both common and distinct regions of copy number alteration","author":"Borczuk","year":"2016","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.bulcan.2017.11.007_bib0340","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/ng.3520","article-title":"Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations","volume":"48","author":"Bueno","year":"2016","journal-title":"Nat Genet"},{"key":"10.1016\/j.bulcan.2017.11.007_bib0345","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1093\/mutage\/get008","article-title":"Differential mutation profiles and similar intronic TP53\u00a0polymorphisms in asbestos-related lung cancer and pleural mesothelioma","volume":"28","author":"Andujar","year":"2013","journal-title":"Mutagenesis"},{"key":"10.1016\/j.bulcan.2017.11.007_bib0350","doi-asserted-by":"crossref","first-page":"3799","DOI":"10.1038\/sj.onc.1206593","article-title":"Hemizygosity of N\u01922\u00a0is associated with increased susceptibility to asbestos-induced peritoneal tumors","volume":"22","author":"Fleury-Feith","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.bulcan.2017.11.007_bib0355","doi-asserted-by":"crossref","first-page":"e18828","DOI":"10.1371\/journal.pone.0018828","article-title":"Losses of both products of the Cdkn2a\/Arf locus contribute to asbestos-induced mesothelioma development and cooperate to accelerate tumorigenesis","volume":"6","author":"Altomare","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.bulcan.2017.11.007_bib0360","doi-asserted-by":"crossref","first-page":"4388","DOI":"10.1158\/0008-5472.CAN-14-1328","article-title":"Germline mutation of Bap1\u00a0accelerates development of asbestos-induced malignant mesothelioma","volume":"74","author":"Xu","year":"2014","journal-title":"Cancer Res"},{"key":"10.1016\/j.bulcan.2017.11.007_bib0365","doi-asserted-by":"crossref","first-page":"3191","DOI":"10.1158\/1078-0432.CCR-16-1971","article-title":"Co-occurring mutations of tumor suppressor genes, LATS2\u00a0and NF2, in malignant pleural mesothelioma","volume":"23","author":"Tranchant","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bulcan.2017.11.007_bib0370","doi-asserted-by":"crossref","first-page":"3748","DOI":"10.1038\/onc.2013.351","article-title":"Overexpression and promoter mutation of the TERT gene in malignant pleural mesothelioma","volume":"33","author":"Tallet","year":"2014","journal-title":"Oncogene"},{"key":"10.1016\/j.bulcan.2017.11.007_bib0375","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1158\/1078-0432.CCR-13-2429","article-title":"Molecular classification of malignant pleural mesothelioma: identification of a poor prognosis subgroup linked to the epithelial-to-mesenchymal transition","volume":"20","author":"de Reynies","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bulcan.2017.11.007_bib0380","doi-asserted-by":"crossref","first-page":"350","DOI":"10.21037\/tlcr.2017.06.06","article-title":"Targeting the epigenome in malignant pleural mesothelioma","volume":"6","author":"McLoughlin","year":"2017","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.bulcan.2017.11.007_bib0385","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1158\/0008-5472.CAN-08-2586","article-title":"Epigenetic profiles distinguish pleural mesothelioma from normal pleura and predict lung asbestos burden and clinical outcome","volume":"69","author":"Christensen","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.bulcan.2017.11.007_bib0390","doi-asserted-by":"crossref","first-page":"9073","DOI":"10.1158\/0008-5472.CAN-09-1595","article-title":"Epigenetic profiles distinguish malignant pleural mesothelioma from lung adenocarcinoma","volume":"69","author":"Goto","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.bulcan.2017.11.007_bib0395","first-page":"1031","article-title":"MicroRNAs in mesothelioma: from tumor suppressors and biomarkers to therapeutic targets","volume":"7","author":"Reid","year":"2015","journal-title":"J Thorac Dis"},{"key":"10.1016\/j.bulcan.2017.11.007_bib0400","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1165\/rcmb.2009-0060OC","article-title":"MicroRNA signature of malignant mesothelioma with potential diagnostic and prognostic implications","volume":"42","author":"Busacca","year":"2010","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.bulcan.2017.11.007_bib0405","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1378\/chest.125.5.1843","article-title":"Gene expression profiling identifies matriptase overexpression in malignant mesothelioma","volume":"125","author":"Hoang","year":"2004","journal-title":"Chest"},{"key":"10.1016\/j.bulcan.2017.11.007_bib0410","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1016\/S0002-9440(10)62492-3","article-title":"Identification of novel candidate oncogenes and tumor suppressors in malignant pleural mesothelioma using large-scale transcriptional profiling","volume":"166","author":"Gordon","year":"2005","journal-title":"Am J Pathol"},{"key":"10.1016\/j.bulcan.2017.11.007_bib0415","doi-asserted-by":"crossref","first-page":"5686","DOI":"10.1158\/0008-5472.CAN-10-0190","article-title":"Integrated profiling reveals a global correlation between epigenetic and genetic alterations in mesothelioma","volume":"70","author":"Christensen","year":"2010","journal-title":"Cancer Res"},{"key":"10.1016\/j.bulcan.2017.11.007_bib0420","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ccell.2014.12.001","article-title":"Biological and therapeutic impact of intratumor heterogeneity in cancer evolution","volume":"27","author":"McGranahan","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bulcan.2017.11.007_bib0425","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.lungcan.2016.07.011","article-title":"Low homozygous\/high heterozygous deletion status by p16\u00a0FISH correlates with a better prognostic group than high homozygous deletion status in malignant pleural mesothelioma","volume":"99","author":"Hamasaki","year":"2016","journal-title":"Lung Cancer"},{"key":"10.1016\/j.bulcan.2017.11.007_bib0430","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1186\/s12967-014-0301-3","article-title":"Evaluation of clonal origin of malignant mesothelioma","volume":"12","author":"Comertpay","year":"2014","journal-title":"J Transl Med"},{"key":"10.1016\/j.bulcan.2017.11.007_bib0435","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0272-5231(05)70074-5","article-title":"Anatomy of the pleura","volume":"19","author":"Wang","year":"1998","journal-title":"Clin Chest Med"},{"key":"10.1016\/j.bulcan.2017.11.007_bib0440","doi-asserted-by":"crossref","first-page":"e1278330","DOI":"10.1080\/2162402X.2016.1278330","article-title":"Integrated analysis of somatic mutations and immune microenvironment in malignant pleural mesothelioma","volume":"6","author":"Kiyotani","year":"2017","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.bulcan.2017.11.007_bib0445","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/nrc.2017.42","article-title":"Novel insights into mesothelioma biology and implications for therapy","volume":"17","author":"Yap","year":"2017","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.bulcan.2017.11.007_bib0450","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1126\/scitranslmed.3008639","article-title":"Merlin deficiency predicts FAK inhibitor sensitivity: a synthetic lethal relationship","volume":"6","author":"Shapiro","year":"2014","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.bulcan.2017.11.007_bib0455","doi-asserted-by":"crossref","first-page":"5522","DOI":"10.1038\/onc.2017.147","article-title":"E-cadherin expression is correlated with focal adhesion kinase inhibitor resistance in Merlin-negative malignant mesothelioma cells","volume":"36","author":"Kato","year":"2017","journal-title":"Oncogene"},{"key":"10.1016\/j.bulcan.2017.11.007_bib0230","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.jtho.2017.02.013","article-title":"The immune microenvironment, genome-wide copy number aberrations, and survival in mesothelioma","volume":"12","author":"Thapa","year":"2017","journal-title":"J Thorac Oncol"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455117303740?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455117303740?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,7,9]],"date-time":"2018-07-09T07:11:41Z","timestamp":1531120301000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455117303740"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["S0007455117303740"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2017.11.007","relation":{},"ISSN":["0007-4551"],"issn-type":[{"value":"0007-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"H\u00e9t\u00e9rog\u00e9n\u00e9it\u00e9 mol\u00e9culaire des m\u00e9soth\u00e9liomes pleuraux malins","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2017.11.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}